[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646121":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":43,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":68,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Henan Cancer Hospital","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"R\u002FR B-NHL treated with bispecific antibody",null,"Patients with relapsed or refractory B-cell non-Hodgkin lymphoma who receive a CD20xCD3 bispecific antibody-containing regimen (e.g., glofitamab) in routine clinical practice. This is a single observational cohort; no treatment is assigned by the study.",[13],"Biological: Glofitamab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"BIOLOGICAL","Glofitamab","Glofitamab, a CD20xCD3 bispecific monoclonal antibody, administered per real-world clinical practice and product labeling. As an observational study, treatment is determined by the treating physician and not by the study protocol; the intervention of interest is recorded to describe the treated population.",[9],[21],{"name":22,"affiliation":5,"role":23},"Yanyan Liu","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","+86 13838176375","yyliu@zzu.edu.cn",[30],{"facility":5,"status":10,"city":31,"state":32,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Zhengzhou","Henan","China","CN",{"type":36,"coordinates":37},"Point",[38,39],113.64861,34.75778,{"lat":39,"lon":38},[42],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},{"type":44,"investigatorFullName":22,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Professor","100646121","real-world-study-of-bispecific-antibody-in-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma-100646121",false,"NCT07695896","Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","A Real-World Study on the Efficacy and Safety of Bispecific Antibody in the Treatment of Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Age \\>= 18 years at the start of treatment\n* Histologically confirmed B-cell non-Hodgkin lymphoma\n* Relapsed or refractory disease after at least one prior line of systemic therapy\n* Planned to receive a CD20xCD3 bispecific antibody-containing regimen after study initiation\n* Signed informed consent for the investigational treatment\n\nExclusion Criteria:\n\n* Currently participating in, or planning to participate in, any interventional clinical trial\n* Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study","ALL","18 Years",{"count":56,"type":57},200,"ESTIMATED","OBSERVATIONAL","B-cell non-Hodgkin lymphoma (B-NHL) is the most common type of lymphoma. Although first-line R-CHOP can cure a proportion of patients, approximately 30%-40% relapse or become refractory (R\u002FR). CD20xCD3 bispecific antibodies, represented by glofitamab, have shown significant efficacy in clinical trials. However, large-scale real-world efficacy and safety data in Chinese clinical practice are still lacking, particularly regarding combination with different regimens and use in the relapsed population.\n\nThis is a prospective, multicenter, observational registry study evaluating the efficacy and safety of CD20xCD3 bispecific antibody-containing regimens in patients with relapsed or refractory B-cell non-Hodgkin lymphoma in a real-world setting. Efficacy is assessed using the Lugano 2014 response criteria. The primary endpoint is best objective response rate (ORR).",[61],"Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",[63,64,17,65,66,67],"B-cell non-Hodgkin lymphoma","Bispecific antibody","CD20xCD3","Real-world study","Relapsed refractory","NOT_YET_RECRUITING","2026-07-06",{"date":71,"type":72},"2026-07-10","ACTUAL",{"date":74,"type":57},"2026-07",{"date":76,"type":57},"2028-12",{"name":22,"class":6},1]